Schroder Investment Management Group raised its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 38.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 22,287 shares of the medical research company’s stock after buying an additional 6,138 shares during the period. Schroder Investment Management Group’s holdings in Charles River Laboratories International were worth $2,383,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Legal & General Group Plc lifted its position in shares of Charles River Laboratories International by 15.8% during the 3rd quarter. Legal & General Group Plc now owns 46,119 shares of the medical research company’s stock worth $4,982,000 after purchasing an additional 6,287 shares during the last quarter. Amundi Pioneer Asset Management Inc. lifted its position in shares of Charles River Laboratories International by 32.8% during the 3rd quarter. Amundi Pioneer Asset Management Inc. now owns 131,661 shares of the medical research company’s stock worth $14,222,000 after purchasing an additional 32,551 shares during the last quarter. Eagle Boston Investment Management Inc. lifted its position in shares of Charles River Laboratories International by 2.3% during the 3rd quarter. Eagle Boston Investment Management Inc. now owns 86,418 shares of the medical research company’s stock worth $9,413,000 after purchasing an additional 1,918 shares during the last quarter. Eagle Asset Management Inc. lifted its position in shares of Charles River Laboratories International by 5.2% during the 3rd quarter. Eagle Asset Management Inc. now owns 321,341 shares of the medical research company’s stock worth $35,003,000 after purchasing an additional 16,016 shares during the last quarter. Finally, Nordea Investment Management AB lifted its position in shares of Charles River Laboratories International by 115.0% during the 3rd quarter. Nordea Investment Management AB now owns 169,754 shares of the medical research company’s stock worth $18,337,000 after purchasing an additional 90,784 shares during the last quarter. 96.27% of the stock is owned by institutional investors.

Shares of Charles River Laboratories International, Inc. (NYSE CRL) opened at $106.00 on Thursday. Charles River Laboratories International, Inc. has a 1 year low of $73.81 and a 1 year high of $119.05. The firm has a market cap of $4,952.59, a price-to-earnings ratio of 20.54, a P/E/G ratio of 1.67 and a beta of 0.89. The company has a quick ratio of 1.62, a current ratio of 1.88 and a debt-to-equity ratio of 1.13.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. The firm had revenue of $464.23 million during the quarter, compared to analysts’ expectations of $458.93 million. During the same period in the previous year, the company earned $1.18 earnings per share. Charles River Laboratories International’s quarterly revenue was up 9.0% compared to the same quarter last year. equities analysts predict that Charles River Laboratories International, Inc. will post 5.13 EPS for the current year.

Several equities research analysts have recently issued reports on CRL shares. Credit Suisse Group reaffirmed a “neutral” rating and set a $112.00 price objective (up from $95.00) on shares of Charles River Laboratories International in a research report on Monday, October 16th. Zacks Investment Research raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $129.00 price objective for the company in a research report on Tuesday, October 24th. ValuEngine cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Jefferies Group reaffirmed a “buy” rating and set a $120.00 price objective on shares of Charles River Laboratories International in a research report on Tuesday, September 12th. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $113.00 price objective on shares of Charles River Laboratories International in a research report on Friday, November 17th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Charles River Laboratories International has a consensus rating of “Buy” and an average target price of $107.65.

In related news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the business’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $0.27, for a total value of $270,000.00. Also, insider Davide Molho sold 6,165 shares of the business’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $110.00, for a total transaction of $678,150.00. The disclosure for this sale can be found here. Over the last three months, insiders purchased 10,500 shares of company stock valued at $2,885 and sold 1,056,776 shares valued at $2,011,952. 2.20% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/schroder-investment-management-group-acquires-6138-shares-of-charles-river-laboratories-international-inc-crl/1763348.html.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with Analyst Ratings Network's FREE daily email newsletter.